Skip to main content
LIMN logo

Liminatus Pharma, Inc. (LIMN) Stock Price & Analysis

Liminatus Pharma, Inc. (LIMN) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $2.51 (-10.68%), as of the Nov 20, 2026 trading session; market cap $3.37M.

Educational signal · not a buy or sell recommendation · How to read this

$2.51 −$0.30 (-10.68%) Market Cap $3.37M

Liminatus Pharma, Inc. · LIMN · NASDAQ

Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company focused on developing novel cancer therapies. The company is based in La Palma, California and operates within the healthcare sector.

Price as of Nov 20, 2026

Key Statistics

29 of 100

MoonshotScore v2 · Liminatus Pharma (LIMN)

Weak
Business Quality Thin (38)
Financial Safety Fragile (14)
Valuation Bubble (1)
Growth Durability Fading (20)
Momentum Falling (17)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, a fragile balance sheet, stalling growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Falling.

Earnings yield is the main valuation drag relative to sector peers.

  • quarterly revenue $0 (Q2 FY2026, quarter ended Jun 2026)
  • Altman Z -28.22 · Piotroski F 2
  • ROE 443.6% · current ratio 1.12 · free-cash-flow yield -99.2%

Holding back: balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LIMN (58 recorded, newest six shown)
RecordedScoreBand
27Weak
27Weak
27Weak
29Weak
29Weak
29Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$2.51
Change on the day-10.68%
Market capitalisation$3.37M—
Shares traded on the day61.9K

Price & events

Other perspectives

Council score for Liminatus Pharma (LIMN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Negative
Valuation Negative
Growth Durability Weak
Momentum Negative

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Unfavorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Negative
ROE Strong
Gross Margin Negative

Read on: Nov 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Liminatus Pharma (LIMN), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Liminatus Pharma, Inc. (LIMN) is listed on NASDAQ. It employs 1 people. In Q2 FY2026 it reported revenue of $0 and net income of -$1M. The market values it at $3.37M.

2 · Latest results

What do the latest results show for Liminatus Pharma (LIMN)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $0.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$0-$1M-$2.96 (diluted)
Q1 FY2026$0-$1M-$2.37 (diluted)
Q4 FY2025$0-$8M-$17.20 (diluted)
Q3 FY2025$0-$2M-$3.38 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Liminatus Pharma (LIMN)?

Short answer · as of

What is holding it back is balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -28.22 · Piotroski F 2. Trailing ratios: ROE 443.6% · current ratio 1.12 · free-cash-flow yield -99.2%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -28.22 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Liminatus Pharma compare with its peers?

Short answer

Liminatus Pharma's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.47 Nov 20, 2026$86.6M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$11.54 Nov 20, 2026$817M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.43 Nov 20, 2026$1.02B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$7.98 Nov 20, 2026$780M63 5-pillar Nov 18, 2026
Liminatus Pharma (LIMN) — this page$2.51$3.37M29

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 2, 2026

Transactions
2
Identified insiders
1
Purchases
0
Sales
0
Other transactions
2

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LIMN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LIMN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Liminatus Pharma (LIMN)?

Read these with our analysis →

Common Questions About LIMN

These answers are editorial: 1 of these 9 answers is drawn from the LIMN research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for LIMN?

LIMN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company focused on developing novel cancer therapies.

Is LIMN a good stock to buy?

Stock Expert AI does not rate LIMN buy, sell or hold. Liminatus Pharma, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LIMN stock price today?

The last price recorded for Liminatus Pharma, Inc. (LIMN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for LIMN?

Liminatus Pharma, Inc. faces several significant risks inherent to the biotechnology industry. These include the uncertainty of clinical trial outcomes, the need for substantial additional funding, and intense competition from larger, more established players. Regulatory hurdles and delays in obtaining approvals for its therapies also pose a risk. The company's small size and limited resources further amplify these challenges.

What are the key factors to evaluate for LIMN?

Liminatus Pharma, Inc. (LIMN) holds a MoonshotScore in the low range. The company has a small team of three employees, reflecting a lean operational structure. Not financial advice.

How frequently does LIMN data refresh on this page?

LIMN's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LIMN's recent stock price performance?

Liminatus Pharma, Inc. (LIMN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on immuno-oncology, a rapidly growing field. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LIMN overvalued or undervalued right now?

Liminatus Pharma, Inc. (LIMN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of LIMN?

Fractional-share availability for Liminatus Pharma, Inc. (LIMN) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 9 from Financial Modeling Prep (FMP), 3 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.